 | • レポートコード：MRC2-11QY03969 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は次世代抗体療法のグローバル市場について調査・分析したレポートです。種類別（抗体薬物複合体（ADC）、二重特異性抗体（BsAbs）、Fc改変抗体、抗体フラグメントおよび抗体様タンパク質（AFおよびALP）、バイオシミラー抗体（Ab）製品）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別次世代抗体療法の競争状況、市場シェア ・世界の次世代抗体療法市場：種類別市場規模 2015年-2020年（抗体薬物複合体（ADC）、二重特異性抗体（BsAbs）、Fc改変抗体、抗体フラグメントおよび抗体様タンパク質（AFおよびALP）、バイオシミラー抗体（Ab）製品） ・世界の次世代抗体療法市場：種類別市場規模予測 2021年-2026年（抗体薬物複合体（ADC）、二重特異性抗体（BsAbs）、Fc改変抗体、抗体フラグメントおよび抗体様タンパク質（AFおよびALP）、バイオシミラー抗体（Ab）製品） ・世界の次世代抗体療法市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の次世代抗体療法市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の次世代抗体療法市場分析：米国、カナダ ・ヨーロッパの次世代抗体療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの次世代抗体療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の次世代抗体療法市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの次世代抗体療法市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Roche、Bristol-Myers Squibb、Amgen、AstraZeneca、Bayer、Takeda Pharmaceuticals、Biogen、Seattle Genetics、ImmunoGen、Kyowa Hakko Kirin、Xencor、Dyax Corp ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period.
Market Analysis and Insights: Global Next Generation Antibody Therapeutics Market
The global Next Generation Antibody Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Next Generation Antibody Therapeutics Scope and Market Size
Next Generation Antibody Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Next Generation Antibody Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Bayer
Takeda Pharmaceuticals
Biogen
Seattle Genetics
ImmunoGen
Kyowa Hakko Kirin
Xencor
Dyax Corp
Market segment by Type, the product can be split into
Antibody Drug Conjugates (ADCs)
Bispecific Antibodies (BsAbs)
Fc Engineered Antibodies
Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Biosimilar Antibody (Ab) Products
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Antibody Drug Conjugates (ADCs)
1.4.3 Bispecific Antibodies (BsAbs)
1.4.4 Fc Engineered Antibodies
1.4.5 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
1.4.6 Biosimilar Antibody (Ab) Products
1.5 Market by Application
1.5.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2015-2026)
2.2 Global Next Generation Antibody Therapeutics Growth Trends by Regions
2.2.1 Next Generation Antibody Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Next Generation Antibody Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Next Generation Antibody Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Next Generation Antibody Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Antibody Therapeutics Players by Market Size
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.2.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2019
3.3 Next Generation Antibody Therapeutics Key Players Head office and Area Served
3.4 Key Players Next Generation Antibody Therapeutics Product Solution and Service
3.5 Date of Enter into Next Generation Antibody Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2015-2020)
6.2 Next Generation Antibody Therapeutics Key Players in North America (2019-2020)
6.3 North America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
6.4 North America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2015-2020)
7.2 Next Generation Antibody Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Next Generation Antibody Therapeutics Market Size (2015-2020)
8.2 Next Generation Antibody Therapeutics Key Players in China (2019-2020)
8.3 China Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
8.4 China Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Next Generation Antibody Therapeutics Market Size (2015-2020)
9.2 Next Generation Antibody Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
9.4 Japan Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Next Generation Antibody Therapeutics Market Size (2015-2020)
10.2 Next Generation Antibody Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Next Generation Antibody Therapeutics Market Size (2015-2020)
11.2 Next Generation Antibody Therapeutics Key Players in India (2019-2020)
11.3 India Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
11.4 India Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Next Generation Antibody Therapeutics Market Size (2015-2020)
12.2 Next Generation Antibody Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Next Generation Antibody Therapeutics Introduction
13.1.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Next Generation Antibody Therapeutics Introduction
13.2.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Bristol-Myers Squibb
13.3.1 Bristol-Myers Squibb Company Details
13.3.2 Bristol-Myers Squibb Business Overview
13.3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Introduction
13.3.4 Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.3.5 Bristol-Myers Squibb Recent Development
13.4 Amgen
13.4.1 Amgen Company Details
13.4.2 Amgen Business Overview
13.4.3 Amgen Next Generation Antibody Therapeutics Introduction
13.4.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.4.5 Amgen Recent Development
13.5 AstraZeneca
13.5.1 AstraZeneca Company Details
13.5.2 AstraZeneca Business Overview
13.5.3 AstraZeneca Next Generation Antibody Therapeutics Introduction
13.5.4 AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.5.5 AstraZeneca Recent Development
13.6 Bayer
13.6.1 Bayer Company Details
13.6.2 Bayer Business Overview
13.6.3 Bayer Next Generation Antibody Therapeutics Introduction
13.6.4 Bayer Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.6.5 Bayer Recent Development
13.7 Takeda Pharmaceuticals
13.7.1 Takeda Pharmaceuticals Company Details
13.7.2 Takeda Pharmaceuticals Business Overview
13.7.3 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Introduction
13.7.4 Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.7.5 Takeda Pharmaceuticals Recent Development
13.8 Biogen
13.8.1 Biogen Company Details
13.8.2 Biogen Business Overview
13.8.3 Biogen Next Generation Antibody Therapeutics Introduction
13.8.4 Biogen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.8.5 Biogen Recent Development
13.9 Seattle Genetics
13.9.1 Seattle Genetics Company Details
13.9.2 Seattle Genetics Business Overview
13.9.3 Seattle Genetics Next Generation Antibody Therapeutics Introduction
13.9.4 Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.9.5 Seattle Genetics Recent Development
13.10 ImmunoGen
13.10.1 ImmunoGen Company Details
13.10.2 ImmunoGen Business Overview
13.10.3 ImmunoGen Next Generation Antibody Therapeutics Introduction
13.10.4 ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
13.10.5 ImmunoGen Recent Development
13.11 Kyowa Hakko Kirin
10.11.1 Kyowa Hakko Kirin Company Details
10.11.2 Kyowa Hakko Kirin Business Overview
10.11.3 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Introduction
10.11.4 Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
10.11.5 Kyowa Hakko Kirin Recent Development
13.12 Xencor
10.12.1 Xencor Company Details
10.12.2 Xencor Business Overview
10.12.3 Xencor Next Generation Antibody Therapeutics Introduction
10.12.4 Xencor Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
10.12.5 Xencor Recent Development
13.13 Dyax Corp
10.13.1 Dyax Corp Company Details
10.13.2 Dyax Corp Business Overview
10.13.3 Dyax Corp Next Generation Antibody Therapeutics Introduction
10.13.4 Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
10.13.5 Dyax Corp Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Next Generation Antibody Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
Table 3. Ranking of Global Top Next Generation Antibody Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Antibody Drug Conjugates (ADCs)
Table 6. Key Players of Bispecific Antibodies (BsAbs)
Table 7. Key Players of Fc Engineered Antibodies
Table 8. Key Players of Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Table 9. Key Players of Biosimilar Antibody (Ab) Products
Table 10. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Next Generation Antibody Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Next Generation Antibody Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Next Generation Antibody Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Next Generation Antibody Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Next Generation Antibody Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Next Generation Antibody Therapeutics Players
Table 21. Global Next Generation Antibody Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Next Generation Antibody Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next Generation Antibody Therapeutics as of 2019)
Table 24. Global Next Generation Antibody Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Next Generation Antibody Therapeutics Product Solution and Service
Table 27. Date of Enter into Next Generation Antibody Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Next Generation Antibody Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Next Generation Antibody Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Next Generation Antibody Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 37. North America Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 39. North America Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 43. Europe Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 49. China Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 51. China Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 55. Japan Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 67. India Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 69. India Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Next Generation Antibody Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Next Generation Antibody Therapeutics Market Share (2019-2020)
Table 73. Central & South America Next Generation Antibody Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Next Generation Antibody Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Next Generation Antibody Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Next Generation Antibody Therapeutics Market Share by Application (2015-2020)
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Product
Table 80. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 81. Pfizer Recent Development
Table 82. Roche Company Details
Table 83. Roche Business Overview
Table 84. Roche Product
Table 85. Roche Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 86. Roche Recent Development
Table 87. Bristol-Myers Squibb Company Details
Table 88. Bristol-Myers Squibb Business Overview
Table 89. Bristol-Myers Squibb Product
Table 90. Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 91. Bristol-Myers Squibb Recent Development
Table 92. Amgen Company Details
Table 93. Amgen Business Overview
Table 94. Amgen Product
Table 95. Amgen Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 96. Amgen Recent Development
Table 97. AstraZeneca Company Details
Table 98. AstraZeneca Business Overview
Table 99. AstraZeneca Product
Table 100. AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 101. AstraZeneca Recent Development
Table 102. Bayer Company Details
Table 103. Bayer Business Overview
Table 104. Bayer Product
Table 105. Bayer Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 106. Bayer Recent Development
Table 107. Takeda Pharmaceuticals Company Details
Table 108. Takeda Pharmaceuticals Business Overview
Table 109. Takeda Pharmaceuticals Product
Table 110. Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 111. Takeda Pharmaceuticals Recent Development
Table 112. Biogen Business Overview
Table 113. Biogen Product
Table 114. Biogen Company Details
Table 115. Biogen Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 116. Biogen Recent Development
Table 117. Seattle Genetics Company Details
Table 118. Seattle Genetics Business Overview
Table 119. Seattle Genetics Product
Table 120. Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 121. Seattle Genetics Recent Development
Table 122. ImmunoGen Company Details
Table 123. ImmunoGen Business Overview
Table 124. ImmunoGen Product
Table 125. ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 126. ImmunoGen Recent Development
Table 127. Kyowa Hakko Kirin Company Details
Table 128. Kyowa Hakko Kirin Business Overview
Table 129. Kyowa Hakko Kirin Product
Table 130. Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 131. Kyowa Hakko Kirin Recent Development
Table 132. Xencor Company Details
Table 133. Xencor Business Overview
Table 134. Xencor Product
Table 135. Xencor Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 136. Xencor Recent Development
Table 137. Dyax Corp Company Details
Table 138. Dyax Corp Business Overview
Table 139. Dyax Corp Product
Table 140. Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2015-2020) (Million US$)
Table 141. Dyax Corp Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next Generation Antibody Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Antibody Drug Conjugates (ADCs) Features
Figure 3. Bispecific Antibodies (BsAbs) Features
Figure 4. Fc Engineered Antibodies Features
Figure 5. Antibody Fragments and Antibody-Like Proteins (AF & ALPs) Features
Figure 6. Biosimilar Antibody (Ab) Products Features
Figure 7. Global Next Generation Antibody Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Next Generation Antibody Therapeutics Report Years Considered
Figure 12. Global Next Generation Antibody Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Next Generation Antibody Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Next Generation Antibody Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Next Generation Antibody Therapeutics Market Share by Players in 2019
Figure 17. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next Generation Antibody Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2019
Figure 19. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Next Generation Antibody Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
抗体薬物複合体（ADC）の世界市場（～2026年） Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased…- バイオシミラーモノクローナル抗体の世界市場（～2026年） Biosimilar monoclonal antibodies (mAbs) are complex, large proteins of the biosimilar family used by the immune system to identify and neutralize foreign bodies, such as bacteria, viruses, and others. These antibodies are normally administered in the treatment of diseases such as rheumatoid arthriti…
- 併用抗体療法の世界市場（～2026年） Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination ant…
- B3GL2抗体の世界市場（～2026年） Market Analysis and Insights: Global B3GL2 Antibody Market The global B3GL2 Antibody market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global B3GL2 Antibody Scope and Market Size B3GL2 Antibody market is segmented by Type, and …
- モノクローナル抗体療法の世界市場（～2026年） Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…